三(3-甲氧基苯基)膦 | 29949-84-6

• 物质功能分类: 有机原料 - 有机膦化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 三(3-甲氧基苯基)膦
• 中文别名: 三（3-甲氧基苯基）膦；三(3-甲氧苯基)膦；三(3-甲氧基苯基)膦,98%
• 英文名称: tris(3-methoxyphenyl)phosphine
• 英文别名: tris(m-methoxyphenyl)phosphine；tris(3-methoxyphenyl)phosphane；Tri-(m-methoxyphenyl)-phosphin
• CAS: 29949-84-6
• 化学式: C₂₁H₂₁O₃P
• mdl: MFCD00008386
• 分子量: 352.37
• InChiKey: CCXTYQMZVYIQRP-UHFFFAOYSA-N

物化性质

• 熔点：
  113-115 °C(lit.)
• 沸点：
  476.3±40.0 °C(Predicted)
• 稳定性/保质期：
  如果遵照规格使用和储存则不会分解，未有已知危险反应。避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• TSCA：
  No
• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2931900090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

---

Section 1: Product Identification
Chemical Name: Tris(m-methoxyphenyl)phosphine, 97+%
CAS Registry Number: 29949-84-6
Formula: (m-CH3OC6H4)3P
EINECS Number: none
Chemical Family: organophosphine ligand
Synonym: Tris(3-methoxyphenyl)phosphine, Tri(m-anisyl)phosphine

---

Section 2: Composition and Information on Ingredients
Ingredient CAS Number Percent ACGIH (TWA) OSHA (PEL)
Title compound 29949-84-6 100% no data no data

---

Section 3: Hazards Identification
Emergency Overview: Irritating to the respiratory tract, skin and eyes. May be harmful if swallowed.
Primary Routes of Exposure: Ingestion, eyes, inhalation
Eye Contact: Causes slight to mild irritation of the eyes.
Skin Contact: Causes slight to mild irritation of the skin.
Inhalation: Irritating to the nose, mucous membranes and respiratory tract.
No specific information is available on the physiological effects of ingestion. May cause vomiting and diarrhea.
Ingestion:
Acute Health Affects: Irritating to skin, eyes and respiratory tract.
Chronic Health Affects: No information available on long-term chronic effects.
NTP: No
IARC: No
OSHA: No

---

SECTION 4: First Aid Measures
Immediately flush the eyes with copious amounts of water for at least 10-15 minutes. A victim may need
Eye Exposure:
assistance in keeping their eye lids open. Get immediate medical attention.
Wash the affected area with water. Remove contaminated clothes if necessary. Seek medical assistance if
Skin Exposure:
irritation persists.
Remove the victim to fresh air. Closely monitor the victim for signs of respiratory problems, such as difficulty
Inhalation:
in breathing, coughing, wheezing, or pain. In such cases seek immediate medical assistance.
Seek medical attention immediately. Keep the victim calm. Give the victim water (only if conscious). Induce
Ingestion:
vomiting only if directed by medical personnel.

---

SECTION 5: Fire Fighting Measures
Flash Point: none
Autoignition Temperature: none
Explosion Limits: none
Extinguishing Medium: carbon dioxide, dry powder or foam
Fire fighters should be equipped with a NIOSH approved positive pressure self-contained breathing apparatus
Special Fire Fighting Procedures:
and full protective clothing.
Hazardous Combustion and If involved in a fire this material may emit toxic organic fumes.
Decomposion Products:
Unusual Fire or Explosion Hazards: Fine dust may form flammable mixtures with air. Handle the material in an efficient fume hood.

---

SECTION 6: Accidental Release Measures
Spill and Leak Procedures: Small spills can be mixed with vermiculite or sodium carbonate and swept up.

---

SECTION 7: Handling and Storage
Handling and Storage: Store in a tightly sealed container. Keep away from heat and direct sunlight.

---

SECTION 8: Exposure Controls and Personal Protection
Eye Protection: Always wear approved safety glasses when handling a chemical substance in the laboratory.
Skin Protection: Wear protective clothing and gloves.
Ventilation: Material may form a fine dust. If possible, handle the material in an efficient fume hood.
If ventilation is not available a respirator should be worn. The use of respirators requires a Respirator
Respirator:
Protection Program to be in compliance with 29 CFR 1910.134.
Ventilation: Material may form a fine dust. If possible, handle the material in an efficient fume hood.
Additional Protection: No additional protection required.

---

SECTION 9: Physical and Chemical Properties
Color and Form: white xtl.
Molecular Weight: 352.37
Melting Point: 115°
Boiling Point: no data
Vapor Pressure: no data
Specific Gravity: no data
Odor: none
Solubility in Water: insoluble

---

SECTION 10: Stability and Reactivity
Stability: air and moisture-stable solid
Hazardous Polymerization: none
Conditions to Avoid: contact with strong oxidizing agents
Incompatibility: strong oxidizing agents, halogens
Decomposition Products: carbon dioxide, carbon monoxide, phosphorus pentoxide, and organic fumes.

---

SECTION 11: Toxicological Information
No specific information available on this product. Related compounds have been known to affect the nervous
RTECS Data: system. Symptoms of nervous system toxicity (by oral or inhalation route) include tremors, altered reflexes,
loss of muscle coordination, limb weakness, and convulsions.
Carcinogenic Effects: No data available
Mutagenic Effects: No data available
Tetratogenic Effects: No data available

---

SECTION 12: Ecological Information
Ecological Information: No information available

---

SECTION 13: Disposal Considerations
Disposal: Dispose of according to local, state and federal regulations.

---

SECTION 14: Transportation
Shipping Name (CFR): Non-hazardous
Hazard Class (CFR): NA
Additional Hazard Class (CFR): NA
Packaging Group (CFR): NA
UN ID Number (CFR): NA
Shipping Name (IATA): Non-hazardous
Hazard Class (IATA): NA
Additional Hazard Class (IATA): NA
Packaging Group (IATA): NA
UN ID Number (IATA): NA

---

SECTION 15: Regulatory Information
TSCA: not listed on the TSCA inventory
SARA (Title 313): not regulated by Title 313
Second Ingredient: none

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  三(3-甲氧基苯基)膦 在 sodium 作用下， 以 氨 为溶剂， 反应 4.0h， 以76%的产率得到双(3-甲氧基苯基)膦
  参考文献：
  名称：

  Budzelaar, Peter H. M.; Doorn, Johannes A. van; Meijboom, Nico, Recueil des Travaux Chimiques des Pays-Bas, 1991, vol. 110, # 10, p. 420 - 432

  摘要：

  DOI：
• 作为产物：
  描述：

  (3-methoxyphenyl)magnesium bromide 在 乙醚 、 三氯化磷 作用下， 生成 三(3-甲氧基苯基)膦
  参考文献：
  名称：

  118.坐标链接的极性。第二部分 芳族取代对膦亚胺稳定性的影响

  摘要：

  DOI：

  10.1039/jr9370000527
• 作为试剂：
  描述：

  2-溴-4'-氰基苯乙酮 、 endo,anti-tetracyclododecene 、 3-碘代色酮,97 在 三(3-甲氧基苯基)膦 、 palladium diacetate 、 potassium carbonate 作用下， 以 邻二甲苯 为溶剂， 反应 24.0h， 以41%的产率得到(±)-13-oxo-6,6a,7,7a,8,9,10,11,11a,12,12a,13-dodecahydro-7,12:8,11-dimethanobenzo[5,6]indeno[2,1-b]chromene-6-carbonylbenzonitrile
  参考文献：
  名称：

  通过钯催化的[2 + 2 +1]环合反应合成含色酮的多环化合物。

  摘要：

  描述了钯催化的3-碘代色酮，α-溴羰基化合物和四环十二碳烯（TCD）的[2 + 2 + 1]多米诺环化反应。这种方法为具有稠合/桥环系统的各种含色酮的多环化合物提供了一种简便，有效且经济的途径，产率高（高达81％），具有非对映选择性（在所有情况下均为99：1 dr）。

  DOI：

  10.1039/c9ob02690h

文献信息

• Pyrazinyl-substituted naphthalene derivatives
  申请人：——

  公开号：US20010004669A1

  公开（公告）日：2001-06-21

  Compounds of the formula 1 where R 1 is of the formulae 2 R 2 is —R 4 , —O—R 4 , —O—S (O) 2 —R 4 , —NR 4 R 5 , R 4 —(CH 2 ) b —NH(C═X)—(CH 2 )—, R 4 —(CH 2 ) b —O(C═O)NH—(CH 2 ) c —(C═O)NH—, R 4 (C═O)NH—(C═O)NH—, —(CH 2 ) b —NH(C═X)—(CH 2 ) c —R 4 , R 4 —(CH 2 ) b —O(C═)—(CH 2 ) c —, —(CH 2 ) b —O(C═O)—(CH 2 ) c —R 4 , —NH(C═X)NH—R 4 , R 4 —O(C═O)O—, —O(C═)NH—R 4 , R 4 —O(C═O)NH—, —(CH 2 ) b —(C═0)—(CH 2 ) c —R 4 , —NH—S(O) 2 —R 4 , —C(OH)R 4 R 5 , —CH(OH)—R 4 , —(C═O)—NR 4 R 5 , —CN, —NO 2 , substituted C 1 to C 6 alkyl, substituted or unsubstituted C 1 to C 6 alkenyl, or substituted or unsubstituted C 1 to C 6 alkynyl, said substituted moieties substituted with a moiety of the formulae —R 4 , —R 4 R 5 , —O—R 4 , or —S(O) d —R 4 . These compounds are useful psychotherapeutics and are potent serotonin (5-HT 1 ) agonists and antagonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotranmission. The compounds can also be used as centrally acting antihypertensives and vasodilators.

  公式1的化合物，其中R1是公式2，R2是—R4，—O—R4，—O—S(O)2—R4，—NR4R5，R4—(CH2)b—NH(C═X)—(CH2)c—，R4—(CH2)b—O(C═O)NH—(CH2)c—(C═O)NH—，R4(C═O)NH—(C═O)NH—，—(CH2)b—NH(C═X)—(CH2)c—R4，R4—(CH2)b—O(C═)—(CH2)c—，—(CH2)b—O(C═O)—(CH2)c—R4，—NH(C═X)NH—R4，R4—O(C═O)O—，—O(C═)NH—R4，R4—O(C═O)NH—，—(CH2)b—(C═O)—(CH2)c—R4，—NH—S(O)2—R4，—C(OH)R4R5，—CH(OH)—R4，—(C═O)—NR4R5，—CN，—NO2，取代的C1至C6烷基，取代或未取代的C1至C6烯基，或取代或未取代的C1至C6炔基，所述取代基团被公式—R4，—R4R5，—O—R4或—S(O)d—R4的基团取代。这些化合物是有用的精神治疗剂，并且是强效的血清素（5-HT1）激动剂和拮抗剂，可用于治疗抑郁症、焦虑症、饮食失调、肥胖、药物滥用、丛集性头痛、偏头痛、疼痛和慢性阵发性偏头痛以及与血管疾病相关的头痛，以及其他由血清素神经传递不足引起的疾病。这些化合物还可用作中枢作用抗高血压药和血管扩张剂。
• Compositions containing sertraline and a 5-HT.sub.1D receptor agonist or
  申请人：Pfizer Inc.

  公开号：US05597826A1

  公开（公告）日：1997-01-28

  The present invention relates to novel compositions containing the serotonin selective re-uptake inhibitor (SSRI), preferably (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenam ine, and an agonist or antagonist of the serotonin 1 (5-HT.sub.1) receptor and to the use of such compositions for treating or preventing a condition selected from mood disorders, including depression, seasonal affective disorders and dysthmia, anxiety disorders including generalized anxiety disorder and panic disorder; agoraphobia, avoidant personality disorder; social phobia; obsessive compulsive disorder; post-traumatic stress disorder; memory disorders including dementia, amnestic disorders and age-associated memory impairment; disorders of eating behavior, including anorexia nervosa and bulimia nervosa; obesity; cluster headache; migraine; pain; Alzheimer's disease; chronic paroxysmal hemicrania; headache associated with vascular disorders; Parkinson's disease, including dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias; endocrine disorders such as hyperprolactinaemia; vasospasm (particularly in the cerebral vasculature); hypertension; disorders in the gastrointestinal tract where changes in motility and secretion are involved; sexual dysfunction, including premature ejaculation; and chemical dependencies.

  本发明涉及包含选择性5-羟色胺再摄取抑制剂（SSRI），优选（1S-顺）-4-(3,4-二氯苯基)-1,2,3,4-四氢-N-甲基-1-萘胺，以及5-羟色胺1（5-HT1）受体的激动剂或拮抗剂的新组合物，以及使用这样的组合物治疗或预防情绪障碍，包括抑郁症、季节性情感障碍和情绪恶劣，焦虑障碍，包括广泛性焦虑障碍和恐慌障碍；恐旷症，回避性人格障碍；社交恐惧症；强迫症；创伤后应激障碍；记忆障碍，包括痴呆、遗忘障碍和与年龄相关的记忆减退；饮食行为障碍，包括厌食症和贪食症；肥胖；丛集性头痛；偏头痛；疼痛；阿尔茨海默病；慢性阵发性偏头痛；与血管疾病相关的头痛；帕金森病，包括帕金森病性痴呆、神经阻滞剂诱发的帕金森综合症和迟发性运动障碍；内分泌障碍，如高催乳素血症；血管痉挛（特别是在脑血管中）；高血压；涉及运动和分泌变化的胃肠道疾病；性功能障碍，包括早泄；以及化学依赖性。
• An efficient approach to the synthesis of LTB4 and ω-substituted LTB4 metabolites
  作者：Subhash P. Khanapure、Seongjin Kim、John F. Penrose、K.Frank Austen、William S. Powell、Joshua Rokach

  DOI：10.1016/s0040-4039(02)01206-6

  日期：2002.8

  The first total synthesis of the methyl ester of 20-oxo-LTB426 is described. The key synthon 6 is an advanced new intermediate which has been used in the synthesis of LTB41, 20-oxo-LTB4 methyl ester 26, and 20-hydroxy-LTB42. The synthetic 26 has been used to study the cytosolic aldehyde dehydrogenase-catalyzed oxidation of LTB4 to its ω-carboxy metabolite.

  描述了20-氧代-LTB 4 26的甲酯的第一全合成。合成子键6是已经在LTB的合成中使用了先进的新中间体4 1，20-氧代- LTB 4甲基酯26，和20羟基LTB 4 2。合成的26已被用于研究LTB 4胞质醛脱氢酶催化氧化为其ω-羧基代谢产物。
• [EN] RHENIUM COMPLEXES AND METHODS OF USE FOR TREATING CANCER<br/>[FR] COMPLEXES DE RHÉNIUM ET MÉTHODES D'UTILISATION POUR LE TRAITEMENT DU CANCER
  申请人：UNIV CORNELL

  公开号：WO2017223428A1

  公开（公告）日：2017-12-28

  A composition comprising the following structure: (formula I) wherein Re represents a rhenium ion having a +1 charge; (formula II) represents an uncharged bidentate bicyclic ligand bonded to the rhenium (Re) by two ring nitrogen (N) atoms; and L is a neutral ligand independently selected from CO and neutral phosphine molecules, wherein at least one of the L groups is a CO molecule; and X- represents a non-coordinating monovalent anion; wherein (formula II) is unsubstituted or substituted on any of its two rings, and said neutral phosphine molecule may or may not contain a phosphorus atom as a ring phosphorus atom; provided that, if (formula II) is unsubstituted, then one or two of said L groups are selected from said neutral phosphine molecules, with the provision that at least one of the neutral phosphine molecules has a phosphorus atom as a ring phosphorus atom. Methods for treating cancer by administering the above complex are also disclosed.

  以下结构的组成物：(公式I)，其中Re代表一个带有+1电荷的铼离子；(公式II)代表一个未带电的双齿双环配体，通过两个环上的氮(N)原子与铼(Re)结合；L是独立选择的电中性配体，选自CO和电中性磷化氢分子，其中至少一个L基团是CO分子；X-代表一个非配位的单价阴离子；(公式II)未取代或在其任一双环上进行取代，并且所说的电中性磷化氢分子可能含有也可能不含有作为环磷原子的磷原子；条件是，如果(公式II)未取代，则所说的L基团中有一个或两个选自所说的电中性磷化氢分子，并且至少有一个电中性磷化氢分子具有作为环磷原子的磷原子。还公开了通过施用上述复合物来治疗癌症的方法。
• Mild and efficient oxidation of phosphorus(III) compounds with Selectfluor
  作者：Qian Chen、Jiekun Zeng、Xinxing Yan、Yulin Huang、Zhiyun Du、Kun Zhang、Chunxiao Wen

  DOI：10.1016/j.tetlet.2016.06.078

  日期：2016.7

  A novel and efficient oxidation of phosphorus(III) compounds with Selectfluor is described. The reactions smoothly led to the formation of tertiary phosphine oxides, phosphinates, and phosphonates in up to 99% yield under mild conditions in minutes.

  描述了用Selectfluor新型有效地氧化磷（III）化合物。反应在几分钟内在温和条件下平稳地导致叔膦氧化物，次膦酸酯和膦酸酯的形成，产率高达99％。